Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00576121|
Recruitment Status : Withdrawn
First Posted : December 18, 2007
Last Update Posted : June 23, 2016
|Condition or disease|
|Acute Myocardial Infarction|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||August 2011|
|Estimated Study Completion Date :||August 2012|
Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
- To predict left ventricular remodeling after myocardial infarction using serum matrix metalloproteinase measurement with Tl201 SPECT/CT hybrid imaging and MRI. [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00576121
|United States, Connecticut|
|Yale New Haven Hospital|
|New Haven, Connecticut, United States, 06520|
|Principal Investigator:||Albert J Sinusas, MD||Yale University|